Aprea Therapeutics Inc (APRE)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aprea Therapeutics Inc chart...

About the Company

annan naturvetenskaplig och teknisk forskning och utveckling

Exchange

NASDAQ

$M

Total Revenue

3

Employees

$23M

Market Capitalization

-0.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $APRE News

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

1d ago, source: Business Insider

Begin your TipRanks Premium journey today. Aprea Therapeutics (APRE) Company Description: Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and ...

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024

2d ago, source:

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a price target ...

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

3d ago, source:

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective ...

APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023

on MSN ago, source:

APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might ...

Aprea Therapeutics closes equity financing deal valued at up to $34M

14d ago, source:

A precision oncology company that relocated its headquarters to Bucks County from Boston last year has closed a financing ...

FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment

12d ago, source: MyChesCo on MSN

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, has announced that its ...

Atezolizumab Improves Upon Bevacizumab and Chemo in Cervical Cancer

9d ago, source: Cancer Therapy Advisor

Adding atezolizumab to bevacizumab and platinum chemotherapy improved survival outcomes in patients with advanced cervical ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...